Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Comparing the real and perceived cost of adenotonsillectomy using time-driven activity-based costing.

Simmonds JC, Hollis RJ, Tamberino RK, Vecchiotti MA, Scott AR.

Laryngoscope. 2019 Jun;129(6):1347-1353. doi: 10.1002/lary.27648. Epub 2018 Dec 18.

PMID:
30565229
2.

Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Apr;49(4):1274-9. doi: 10.1128/JCM.02437-10. Epub 2011 Feb 2.

3.
4.

Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Feb;49(2):630-7. doi: 10.1128/JCM.02161-10. Epub 2010 Dec 15.

5.

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

Diagn Microbiol Infect Dis. 2010 May;67(1):56-60. doi: 10.1016/j.diagmicrobio.2010.01.001. Epub 2010 Mar 5.

PMID:
20207095
6.

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ.

J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.

7.

In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA.

J Clin Microbiol. 2009 Oct;47(10):3170-7. doi: 10.1128/JCM.00942-09. Epub 2009 Aug 26.

8.

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.

9.

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ; ARTEMIS DISK Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2009 Sep;65(1):27-34. doi: 10.1016/j.diagmicrobio.2009.05.007.

PMID:
19679232
10.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3185-90. doi: 10.1128/JCM.00946-09. Epub 2009 Aug 5.

11.

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN, Pfaller MA.

Diagn Microbiol Infect Dis. 2009 Feb;63(2):233-6. doi: 10.1016/j.diagmicrobio.2008.11.001. Epub 2008 Dec 12.

PMID:
19070452
12.

Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2008 Nov;46(11):3585-90. doi: 10.1128/JCM.01391-08. Epub 2008 Sep 10.

13.

In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2008 Aug;46(8):2568-72. doi: 10.1128/JCM.00535-08. Epub 2008 Jun 18.

14.
15.

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2008 Jan;46(1):150-6. Epub 2007 Nov 21. Erratum in: J Clin Microbiol. 2008 Sep;46(9):3184-5.

16.

Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Diekema DJ, Messer SA, Hollis RJ, Boyken LB, Tendolkar S, Kroeger J, Pfaller MA.

J Clin Microbiol. 2007 Jun;45(6):1974-7. Epub 2007 Feb 14.

17.

Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Messer SA, Diekema DJ, Hollis RJ, Boyken LB, Tendolkar S, Kroeger J, Pfaller MA.

J Clin Microbiol. 2007 Apr;45(4):1322-4. Epub 2007 Jan 31.

19.

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2006 Oct;44(10):3533-8.

20.

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2006 Mar;44(3):760-3.

21.

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA.

J Clin Microbiol. 2006 Feb;44(2):324-6.

22.

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2005 Nov;43(11):5425-7.

23.

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP.

Antimicrob Agents Chemother. 2005 Nov;49(11):4795-7.

24.
26.

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ.

J Clin Microbiol. 2005 May;43(5):2163-7.

27.

Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA.

J Clin Microbiol. 2005 May;43(5):2155-62.

28.

Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.

Gales AC, Pfaller MA, Sader HS, Hollis RJ, Jones RN.

Microb Drug Resist. 2004 Winter;10(4):286-91.

PMID:
15650372
29.

Activities of available and investigational antifungal agents against rhodotorula species.

Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA.

J Clin Microbiol. 2005 Jan;43(1):476-8.

30.
31.

Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli.

Silbert S, Pfaller MA, Hollis RJ, Barth AL, Sader HS.

Infect Control Hosp Epidemiol. 2004 Oct;25(10):847-51.

PMID:
15518027
32.
33.
37.
38.
39.

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN.

Diagn Microbiol Infect Dis. 2004 Feb;48(2):101-5.

PMID:
14972378
40.

Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2004 Jan;42(1):380-3.

41.

Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thiourea.

Silbert S, Boyken L, Hollis RJ, Pfaller MA.

Diagn Microbiol Infect Dis. 2003 Dec;47(4):619-21.

PMID:
14711485
42.

Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 Dec;41(12):5729-31.

43.

Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy.

Colombo AL, Melo AS, Crespo Rosas RF, Salomão R, Briones M, Hollis RJ, Messer SA, Pfaller MA.

Diagn Microbiol Infect Dis. 2003 Aug;46(4):253-7.

PMID:
12944016
44.
45.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 May;41(5):2176-9.

46.
47.

In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs.

Pfaller MA, Messer SA, Boyken L, Hollis RJ, Diekema DJ.

Diagn Microbiol Infect Dis. 2003 Apr;45(4):241-4.

PMID:
12729993
49.
50.

Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Maxwell MJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Diekema DJ, Pfaller MA.

J Clin Microbiol. 2003 Mar;41(3):1087-90.

Supplemental Content

Loading ...
Support Center